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Background: The association of gadolinium-based contrast agents (GBCAs) with nephrogenic systemic fibrosis
(NSF) has led to a heightened awareness towards patients’ renal function. Whereas detailed guidelines exist for the
use of GBCAs in adult patients, best practice is less well defined in children, especially in the very young. We aimed
at identifying current practice with regards to the use of GBCAs in children who undergo Cardiovascular Magnetic
Resonance.
Methods: We conducted a worldwide survey among cardiac imagers with pediatric expertise. The questionnaire
contained 21 questions covering the imagers’ work environments, GBCAs used, monitoring of renal function, and a
special emphasis was placed on the practice in neonates.
Results: The survey yielded 70 replies. The single most commonly used GBCA was gadopentetate dimeglumine
34/70 (49%). Among the respondents, the choice of GBCA was more importantly based on availability 26/70 (37%)
and approval by a pharmaceutical licensing body that most closely reflects the indication 16/70 (23%) than image
quality 7/70 (10%) and side effect profile 8/70 (11%). 55/70 (79%) of respondents performed scans in neonates
<1 week of age and 52/55 (95%) of them used GBCA in neonates. 65/70 (93%) respondents at least assess some of
their patients’ renal functions. Formula-based estimate of glomerular filtration rate is the most popular assessment
method 35/65 (54%). In patients with a glomerular filtration rate < 30 ml/min/1.73 m2 62/70 (89%) of respondents
do not administer gadolinium at all. The single most common side effect of gadolinium was noted to be nausea/
emesis 34/57 (60%) followed by discomfort at injection site 17/57 (30%).
Conclusions: Cardiac imagers are aware of the immature renal function and physiological differences of their
pediatric patients that place them at risk for NSF. Epidemiological data is needed for pediatric cardiovascular
licensure of gadolinium compounds and for the creation of practice guidelines which will replace current-day
practice based on individual clinical judgment.Background
For the majority of Cardiac Magnetic Resonance (CMR)
indications, the application of gadolinium is required.
Over the years, numerous gadolinium-based contrast
agents (GBCAs) have been introduced. Although com-
monly considered safe in the majority of patients,
reports of nephrogenic systemic fibrosis (NSF) since
2000 have led to a heightened awareness towards the
adverse effects of GBCAs. Explicit licensing for cardiac
indications is not available for gadolinium compounds in
adults, let alone in children, although in the United* Correspondence: lars.grosse-wortmann@sickkids.ca
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Avenue, Toronto, ON M5G 1X8, Canada
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distribution, and reproduction in any mediumKingdom, Magnevist is indicated for whole body applica-
tions which can be interpreted to include the heart.
In addition, no GBCA has been approved by the Food
and Drug Administration (FDA) for use in children
<2 years of age, including non-cardiac indications. [1] As
a consequence, radiologists and cardiologists practice
contrast–based CMR, particularly in young children,
using their best judgment of the risk of adverse reactions
versus the benefit of the investigation for the patient’s
management. We aimed at evaluating the current prac-
tice involving the use of GBCAs among pediatric cardiac
imagers. Specifically, we were interested in finding out
which GBCAs are most commonly used and what
type of precautions are undertaken to avoid adverse
drug reactions.BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 2 Number of pediatric CMRs performed each year.
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We conducted a survey among pediatric imaging specia-
lists (cardiologists and radiologists) around the world.
These individuals were identified from three sources:
The directories of the pediatric working group of the
Society of Cardiovascular Magnetic Resonance and of
the imaging working group of the Association for
European Pediatric Cardiology, as well as from personal
contacts. See Additional file 1: Gadolinium Survey for
the questionnaire. The survey contained 21 questions
covering the imagers’ work environments, GBCAs used,
and monitoring of renal function. Special emphasis was
placed on practice in neonates. In total, 175 specialists
were emailed a link to a web-based survey. Of the 175
email recipients, 22 emails were rendered “undeliver-
able” by our emailing system likely due to incorrect or
out dated email addresses. The survey was open for
responses for one month. As practices may vary among
imagers within the same institution, more than one
imager was contacted at select centers.Respondents who performed “100-200” and “200-500” pediatric
CMRs each made up 27% of all respondents. This is followed by
“more than 500” (17%), “50-100” (16%), and “less than 50” (13%).Results
Our survey produced 70 responses for a response rate of
70/153 (46%). Of the 70 respondents, 26/70 (37%) were
radiologists and 44/70 (63%) were cardiologists. The
work settings of respondents are displayed in Figure 1,
as well as the annual number of pediatric CMR studies
performed, Figure 2. Responses were received fromFigure 1 Practice setting of respondents. The majority 92%
practice in “tertiary care centers”, with 7% practicing in “community
hospitals” and 1% in “private practice”.around the world with the majority of respondents from
North America and Europe (Figure 3).
For easier reference we will refer to the individual
GBCAs under their brand name in the remainder of the
text. The single most commonly used GBCAs were
Magnevist 34/70 (49%), followed by Dotarem 12/70
(17%) and MultiHance 8/70 (11%) (Figure 4). Rationales
for using specific GBCAs are given in Figure 5. 26/70
(37%) of respondents chose “availability of the product”
as the single most important reason for using a parti-
cular GBCA, followed by “approval by pharmaceutical
licensing body that most closely matches my indications”
at 16/70 (23%).
55/70 (79%) of the respondents performed scans in
neonates <1 week of age and 52/55 (95%) of them use
GBCA in these patients. Commonly used GBCAs in
neonates were Magnevist 23/48 (48%), Dotarem 10/48
(21%), and MultiHance 8/48 (17%). 42/51 (82%) of
GBCA users in neonates used the same brand of GBCA
as for older children and adolescents.
With NSF as the most severe GBCA related adverse
effect with the exception of anaphylactic reactions, we
assessed the respondents’ practice around the protection
of kidney function. To determine renal function, the pri-
mary method of assessment was a formula-based esti-
mate of glomerular filtration rate (GFR) (35/65 or 54%).
Serum creatinine concentration was used by 20/65
(31%) of respondents and quantification of urine output
by 4/65 (6%). Other methods of assessment included
Figure 3 Respondents’ country of origin. The majority of respondents are from North America: United States (46%) and Canada (16%).
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ation of data, including renal ultrasound if available (1/65)
65/70 (93%) evaluated renal function in some or all of
their patients. Where renal function assessments were
performed selectively (49/70 of 70%), these were done
in patients with active renal disease and/or impaired
renal function 47/49 (96%), patients with a risk factor for
impaired renal function (e.g. vasculitis, arteriopathies)
but no known renal dysfunction 39/49 (79%), and
patients with impaired renal function in the past 39/49,Figure 4 Most commonly used GBCA. “Magnevist” (49%), “Dotarem” (17%(79%). “All neonates” and “all patients <1 week of age” were
evaluated for renal function by 16/49 (33%) and 15/49
(31%), respectively. In patients with severe renal failure
(GFR <30 ml/min/1.73 m2), 61/70 (87%) of respondents
chose not to administer gadolinium at all. A specific
GBCA was used by 4/70 (6%) of respondents. 2/70 (3%)
gave gadolinium, but never double dose. No respondents
claimed to maintain the same practice in patients with a
GFR <30 ml/min/1.73 m2 as in patients with normal or
near-normal renal function.), and “MultiHance” (11%) are the three most commonly used.
Figure 5 Rationale for use of particular GBCA. 37% of respondents indicated “availability (e.g. hospital contract with manufacturer)” as the
most important reason, followed by “approval by pharmaceutical licensing body that most closely matches my indications” (23%). Less important
reasons for particular GBCA use are “price” (13%), “side effect profile” (11%), “image quality” (10%), and “other” (6%).
Figure 6 Most common side effect of GBCA use. “Nausea/
emesis” (60%) and “discomfort at injection site” (30%) are reported
most frequently. “Rash” (7%), “headache” (4%), and “light-
headedness” (0%) are experienced rarely, if at all.
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1.73 m2, 14/70 (20%) of respondents refrained from
giving any GBCA at all while 8/70 (11%) of respondents
identified their practice is unchanged as compared to a
GFR >60 ml/min 1.73 m2. 22/70 (31%) of respondents
indicated the use of GBCA but never “double dose”. In
cases with renal insufficiency, MultiHance 8/25 (32%),
Dotarem 7/25 (28%), and Magnevist 5/25 (20%) were the
most commonly used specific agents. In contrast,
Omniscan, OptiMark, and Ablavar were not used by any
of our respondents in patients with renal failure. 29/67
(43%) of respondents never obtained written consent for
GBCA application while 14/67 (21%) did on occasion
and 23/67 (34%) always (1/67 - 1% obtained written
consent “most of the time”). 12/69 (17%) of respond-
ents claimed they have never encountered a patient
with a GBCA-attributed side effect and 57/69 (83%)
rarely (1-5% of cases) encountered one. The two most
common side effects from GBCA administration in the
respondents’ practice were nausea/emesis 34/57 (60%)
and discomfort at injection site 17/57 (30%). Rash 4/57
(7%), headache 2/57 (4%), light-headedness 0/57 (0%),
and bronchospasm 0/57 (0%) were much less frequent
(Figure 6).
Discussion
Our survey revealed that three different formulas of
GBCAs make up the bulk of contrast media used for
pediatric CMR worldwide today: Magnevist, Dotarem,
and MultiHance. Immediate concerns around patient
safety may not be the decisive factor in selecting specific
GCBA for use. When asked about the single most
important reason for using a particular agent, availability
of the product featured most prominently (37% ofrespondents). Interestingly, image quality and side effect
profile were less (11% each) determinant of the type of
GBCA used. We speculate that the side effect profile is
of lesser significance when choosing an agent because of
the relatively low overall incidence of adverse reactions.
A single center retrospective study identified
adverse drug reactions (ADR) to be 0.0404% based on
158,439 doses administered [2]. It should be remem-
bered, however, that in subpopulations, such as the very
young, patients with renal and/or hepatic impairment,
and cardiovascular diseases, GBCAs carry much higher
ADR rates [3]. Voth and Hahn and their respective
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of all children, more than ten times that of adults [3,4]
and comparable to a neuro-imaging based study by
Lowe et al. [5]. Conversely, a multicenter study of 432
children between 6 months to 18 years of age reported
only 1 mild event after Omniscan or Magnevist applica-
tion at 0.1 mmol/kg [6]. In our survey, and consistent
with previous reports [7], most respondents identified
rare (1-5%) or no side effects associated with GBCA
injection. The majority of these side effects are mild,
mainly consisting of nausea/emesis 34/57 (60%) and dis-
comfort at the injection site 17/57 (30%).
Magnevist was the primary agent in the practice of
approximately half of the cardiac imagers in this survey,
while Omniscan was the first line agent of only 2/70
(3%) of respondents. Omniscan, which held an overall
market share of 34% in 2006, fell out of favor with the
establishment of an association with NSF [8]. First
reported in 2000, this systemic condition is characterized
by a fibrosing dermatopathy in patients with kidney
failure. The discovery of fibrosis in joints, liver, and
other end organs resulted in a name change to nephro-
genic systemic fibrosis [9]. The effects of NSF are debili-
tating and many patients become wheelchair bound. In
2006, Grobner et al. suggested a link between GBCAs,
renal failure, and NSF [10].
It is free gadolinium that has classically been associated
with the occurrence of NSF [8]. Therefore, the more stable
the chelate-gadolinium compound the safer the agent is
assumed to be with regards to NSF. Linear chelates are
considered to have inferior structural stability when com-
pared to GBCAs with a cyclic chelate structure [11].
Unconfounded cases of NSF have been identified with
Omniscan, Magnevist, and Optimark, all of which are
linear. Conversely, cyclic compounds have been associated
with few, if any cases of NSF [8]. In addition to the
molecular configuration of the chelate, ionic chelates, such
as Magnevist and MultiHance provide greater stability than
non-ionic chelates, including Optimark and Omniscan. Re-
cently, it has been suggested that not only free, but also
chelated GBCA can trigger a pro-inflammatory and pro-
fibrotic cascade [12] so that factors other than the chelate
structure likely play a role in the pathogenesis of NSF.
Given their less-well-developed blood–brain barrier
and immature renal function, the use of GBCA in neo-
nates has been cautioned [6]. According to the most
recent FDA information, Omniscan, Magnevist, Multi-
Hance, Gadovist, and Prohance have been approved for
use in pediatric patients >2 years of age, while no GBCA
has been approved for use in children <2 years. Simi-
larly, the European Medicines Agency (EMA) has classi-
fied the use of ‘high-risk’ GBCAs in neonates less than
4 weeks of age as contraindicated and cautioned the use
of any GBCA in pediatric patients less than 1 year of age[13]. Although no agent was specifically licensed for the
use in this patient population, the Commission on
Human Medicines and Pharmcovigilance Expert Advis-
ory Group, both of which are part of the Medicines and
Healthcare products Regulatory Agency in the UK advo-
cated for the use of lowest possible dose of medium-risk
(MultiHance, Primovist, Ablavar) or low-risk agents
(Gadovist, ProHance, Dotarem) for neonates in 2010. A
large portion of the respondents to our survey (79%)
uses GBCAs in neonates. Interestingly, we observed only
minor differences between the single most preferred
agents in neonates versus those used in older children.
The biggest differences between the two patient popula-
tions were seen for Dotarem and MultiHance, which
both increased in “popularity” from 17% to 21% and 11%
to 19%, respectively, with the use in neonates. Dotarem,
as an ionic cyclic chelate, is theorized to provide better
molecular stability which may be of benefit in patients
who are potentially more susceptible to NSF. According
to suggestions by Riccabona et al. for GBCA use in
infants, only cyclic compounds should be used [14]. It is
more difficult to explain the increased use in MultiHance
as it is based on a linear (although ionic) chelate and has
not been approved for use in patients <18 years of age.
The discovery of kidney failure as a major contributing
factor to the development of NSF has heightened aware-
ness towards renal function before gadolinium adminis-
tration [15,16]. Gadolinium is primarily excreted by the
kidneys (>95%). Under normal renal function, the half-
life of most GBCAs is approximately 1.6 hours, with
>95% of gadolinium cleared from the body in 24 hours
[17]. The notable exception among the commonly used
agents is Ablavar with a half-life of 15 hours [18]. In
patients with moderate and severe renal insufficiency the
half-life of GBCA averages 5.6 and 9.2 hours, respect-
ively [19], allowing more time for the generation of and
exposure to free gadolinium.
In general, healthy adults have a normal GFR ≥ 120
ml/min/1.73 m2. According to ACR, CAR, and EMEA
GBCAs should be avoided in patients with acute renal
dysfunction and/or a GFR < 30 ml/min/1.73 m2, if pos-
sible. GBCA is only to be used when it is vitally import-
ant for the patient’s health. The lowest dose possible
for imaging must be given and GBCAs classified as
“high risk” or “group I” by the EMA and ACR, respect-
ively, including Magnevist, Optimark and Omniscan, are
not recommended.
At Massachusetts General Hospital, and mirroring an-
other group’s results, no new patients were identified
with NSF following implementation of renal function
screening [16,20].
93% of pediatric cardiac imagers who completed the
survey estimate GFR in some or all of their patients.
Those who use GFR estimates selectively are primarily
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at present (96%) or in the past (79%), as well as about
patients with a risk factor for impaired renal function
(79%). In comparison, very young age alone was seen as
a reason to check GFR among a much lower proportion
of respondents.
The ACR recommends applying the adult guidelines
to pediatric patients [1]. In light of the physiologically
low GFR in neonates, this would prevent most of these
patients from undergoing CMR. The average GFR in full
term babies is 26 ml/min 1.73 m2, which is similar to
chronic kidney disease class 4 (<30 ml/min 1.73 m2).
Neonates with congenital heart disease who need cardiac
imaging very early in life often struggle with problems of
prematurity, low cardiac output, as well as electrolyte
and/or acid–base disturbances, all which may result in
an even lower GFR. With this in mind, it is interesting
to note that most imaging experts would not give gado-
linium to an older child or adult with similar GFR, but
do so frequently in neonates (at least when renal function
is not assessed). Should we be concerned about giving
gadolinium to neonates or do they not share the same
NSF risk of older individuals with similarly low GFRs be-
cause their condition is physiologic? Also, is the Schwartz
formula the adequate tool for assessing neonatal renal
function? Many factors make accurate renal function as-
sessment in neonates challenging: Perinatal adaptation is
a highly individualized and dynamic process, confounding
any comparison with normal values. Immediately after
birth, the newborn’s serum creatinine concentration mir-
rors the maternal creatinine levels, rather than indicating
neonatal renal function [21].
54% of respondents indicated the Schwartz formula to
be their primary method of renal function evaluation in
neonates, although the shortcomings of this method in
neonates are well recognized. Hahn et al. argued that,
while excretion rates are lower in newborns as compared
to adults, more gadolinium per body weight is elimi-
nated, possibly reducing the risk of NSF despite a low
estimated GFR. In 2009, the Canadian Association of
Radiologists stated that “an estimation of GFR using
serum creatinine levels in children and neonates is not
optimal”, recommended to use “regional judgement” and
recognized the need for refined guidelines in the future
[22]. As an alternative to the Schwartz formula, 31% of
respondents indicated the use of serum creatinine and
6% indicated urine output. Cystatin C-based estimates
promise to be a better estimate of GFR in children than
the Schwartz formula [23], but pediatric reference values
for Cystatin C have not yet been established [24].
Conclusions
Expert cardiac imagers are aware of the risk of NSF in
their pediatric patients. At the same time, practiceheterogeneity around the use of NSF in newborn
patients is prevalent. Epidemiological data is needed for
pediatric cardiovascular licensure of gadolinium com-
pounds and for the creation of practice guidelines which
will replace current-day practice based on individual
clinical judgement. Currently, a trial with Gadovist
including patients less than 2 years of age is underway.
In the meantime, a balanced discussion of the use of
GBCA in neonates must take into account the diagnos-
tic value of CMR in the management of very young
patients with congenital heart disease, such as obstruct-
ive lesions of the aortic arch, and pulmonary atresia with
major pulmonary collateral arteries.Additional file
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